

ACUTE PHASE REACTANTS IN IRRITABLE BOWEL SYNDROME

Mehmet Rami Helvaci (1)
Engin Altintas (1)
Atilla Yalcin (1)
Orhan Ekrem Muftuoglu (1),
Abdulrazak Abyad (2)
Lesley Pocock (3)

(1) Specialist of Internal Medicine, M.D.
(2) Middle-East Academy for Medicine of Aging, M.D.
(3) Medi-WORLD International

Corresponding Author:

Mehmet Rami Helvaci, M.D.
07400, ALANYA, Turkey
Phone: 00-90-506-4708759
Email: mramihelvaci@hotmail.com

Received: March 2022; Accepted: April 2022; Published: May, 2022

Citation: Mehmet Rami Helvaci et al. Obesity may actually be a precirrhotic condition in adults. Middle East Journal of Nursing 2022; 16(1): 27-33 DOI: 10.5742/MEJN2022.9378019

Abstract

Background: Irritable bowel syndrome (IBS) is one of the frequent causes of recurrent upper abdominal discomfort in adults.

Method: Consecutive patients with the IBS and age and sex-matched control cases were studied. IBS was diagnosed according to Rome II criteria in the absence of red flag symptoms including pain, diarrhea interfering with sleep, weight loss, fever, and any pathological finding in physical examination.

Results: The study included 473 patients with the IBS (308 females and 165 males) and 271 control cases. Mean age of the patients was 43.0 years. Interestingly, 65.1% of the patients with IBS were female. Prevalence of smoking was higher in the patients with IBS, significantly (38.4% versus 18.8%, $p < 0.001$). Although the mean height, weight, body mass index, hematocrit value, and systolic and diastolic blood pressures were similar in both groups, erythrocyte sedimentation rate (ESR) (14.6 versus 12.3 mm/h, $p = 0.02$) and C-reactive protein (CRP) (2.9 versus 2.0 mg/L, $p < 0.001$) values were higher in the IBS group, significantly.

Conclusion: Probably IBS is a low-grade inflammatory process initiated by smoking, infections, inflammations, anxiety, depression, sleep disorders, illness fear, and cancer fear-like stresses, and eventually terminates with dysfunctions of the gastrointestinal and genitourinary tracts and elevations of ESR and CRP-like acute phase reactants (APR) in the plasma. The elevated APR will probably terminate with an accelerated atherosclerotic process all over the body and a shortened survival in both genders.

Key words: Irritable bowel syndrome, erythrocyte sedimentation rate, C-reactive protein, chronic endothelial damage, atherosclerosis, smoking, metabolic syndrome

Introduction

Recurrent upper abdominal discomfort may be a frequent cause of applications to the Internal Medicine Polyclinics (1). Although gastroesophageal reflux disease, esophagitis, duodenal and/or gastric ulcers, erosive gastritis and/or duodenitis, celiac disease, chronic pancreatitis, and malignancies are found among possible causes, irritable bowel syndrome (IBS) and chronic gastritis (CG) may be the most common diagnoses. Flatulence, periods of diarrhea and constipation, repeated toilet visits due to urgent evacuation or early filling sensation, excessive straining, feeling of incomplete evacuation, frequency, urgency, reduced feeling of well-being, and eventually disturbed social life are often reported by patients with the IBS. Although many patients relate onset of symptoms to intake of food, and often incriminate specific food items, a meaningful dietary role is doubtful in the IBS. According to literature, nearly 20% of general population have IBS, and it is more common in female gender with unknown reasons, yet (2). Psychological factors seem to precede onset and exacerbation of gut symptoms, and many potentially psychiatric disorders including anxiety, depression, sleep disorders, illness fear, or cancer fear usually coexist with the IBS (3). For example, thresholds for sensations of initial filling, evacuation, urgent evacuation, and utmost tolerance recorded via a rectal balloon significantly decreased by focusing the examiners' attention on gastrointestinal stimuli by reading pictures of gastrointestinal malignancies in patients with the IBS (4). In other words, although IBS is described as a physical disorder according to Rome II guidelines, psychological factors may be crucial for triggering of these physical changes in the body. IBS is actually defined as a brain-gut dysfunction according to the Rome II criteria, and it may have more complex mechanisms affecting various systems of the body via a low-grade inflammatory process on vascular endothelium (5). Eventually, IBS may even terminate with CG, urolithiasis, and hemorrhoids (6-8). Similarly, some authors studied the role of inflammation in the IBS via colonic biopsies in 77 patients (9). Although 38 patients had normal histology, 31 patients demonstrated microscopic inflammation, and eight patients fulfilled criteria for lymphocytic colitis. However, immunohistology revealed increased intraepithelial lymphocytes as well as increased CD3 and CD25 positive cells in lamina propria of the group with "normal" histology. These features were more evident in the microscopic inflammation group who additionally revealed increased neutrophils, mast cells, and natural killer cells. All of these immunopathological abnormalities were the most evident in the lymphocytic colitis group who also demonstrated HLA-DR staining in the crypts and increased CD8 positive cells in the lamina propria (9). A direct link between the immunological activation and IBS symptoms was shown by some other authors, too (10). They demonstrated not only an increased mast cell degranulation in the colon but also a direct correlation between proximity of the mast cells to neuronal elements and severity of pain in the IBS (10). In addition to above findings, there are some evidences for extension of the inflammatory process behind the mucosa. Some authors addressed this issue in ten patients with

severe IBS by examining full-thickness jejunal biopsies obtained via laparoscopy (11). They detected a low-grade infiltration of lymphocytes in myenteric plexus of nine patients, four of whom had an associated increase in intraepithelial lymphocytes and six demonstrated evidence of neuronal degeneration (11). Nine patients had hypertrophy of longitudinal muscles, and seven had abnormalities in number and size of interstitial cells of Cajal (11). The finding of intraepithelial lymphocytosis was consistent with some other reports in the colon and duodenum, too (9, 12). On the other hand, smoking is a well-known cause of chronic endothelial inflammation terminating with an accelerated atherosclerosis-induced end-organ insufficiencies all over the body (13). We tried to understand whether or not there are some significant relationships between smoking, IBS, and acute phase reactants (APR) including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) in the present study.

Material and methods

The study was performed in the Internal Medicine Polyclinic of the Dumlupinar University between August 2005 and March 2007. Consecutive patients with upper abdominal discomfort were taken into the study. Their medical histories including smoking habit, alcohol consumption, urolithiasis, and already used medications were learned. Patients with devastating illnesses including eating disorders, malignancies, acute or chronic renal failure, cirrhosis, hyper- or hypothyroidism, and heart failure were excluded. Current daily smokers at least for six-month and cases with a history of five pack-year were accepted as smokers. Patients with regular alcohol consumption (one drink a day) were accepted as alcoholic. A routine check up procedure including hemogram, ESR, CRP, albumin, creatinine, thyroid function tests, hepatic function tests, markers of hepatitis A, B, C, and human immunodeficiency viruses, urinalysis, a posterior-anterior chest x-ray graphy, an electrocardiogram, a Doppler echocardiogram in case of requirement, an abdominal ultrasonography, and a questionnaire for the IBS was performed. IBS was diagnosed according to Rome II criteria in the absence of red flag symptoms including pain, diarrhea interfering with sleep, weight loss, fever, and any pathological finding in physical examination. Body mass index (BMI) of each case was calculated by measurements of the Same Physician instead of verbal expressions. Weight in kilograms is divided by height in meters squared (14). Office blood pressures (BP) were checked after a 5-minute of rest in seated position with mercury sphygmomanometer. Eventually, all patients with IBS were collected into the first and age and sex-matched controls were collected into the second groups. Mean values of height, weight, BMI, hematocrit, ESR, CRP, and systolic and diastolic BP and prevalence of smoking were detected in each group and compared in between. Mann-Whitney U test, Independent-Samples T test, and comparison of proportions were used as the methods of statistical analyses.

Results

The study included 473 patients with the IBS (308 females and 165 males) and 271 control cases. Mean age of the patients was 43.0 ± 13.6 (17-76) years. Interestingly, 65.1% of the patients with IBS were female. Prevalence of smoking was higher in the patients with IBS, significantly (38.4% versus 18.8%, $p < 0.001$). Although the mean height, weight, BMI, hematocrit value, and systolic and diastolic BP were similar in both groups, ESR (14.6 versus 12.3 mm/h, $p = 0.02$) and CRP values (2.9 versus 2.0 mg/L, $p < 0.001$) were higher in the IBS group, significantly (Table 1). Due to the limited number of cases with alcoholism, regular alcohol consumption was not included in comparison.

Table 1: Comparison of patients with irritable bowel syndrome and control cases

Variables	Patients with IBS*	p-value	Control cases
Number	473		271
Female ratio	65.1%	Ns†	66.0%
Mean age (year)	<u>43.0 ± 13.6 (17-76)</u>	Ns	43.1 ± 12.3 (13-66)
Smoking	38.4%	<u><0.001</u>	18.8%
Weight (kg)	74.5 ± 15.2 (42-122)	Ns	74.6 ± 15.6 (44-129)
Height (cm)	163.8 ± 9.3 (142-194)	Ns	164.4 ± 9.3 (138-187)
BMI‡ (kg/m ²)	27.7 ± 5.8 (15.0-51.1)	Ns	27.6 ± 5.6 (17.8-49.0)
Systolic BP§ (mmHg)	128.7 ± 25.0 (80-240)	Ns	131.5 ± 27.5 (80-220)
Diastolic BP (mmHg)	89.1 ± 12.9 (50-130)	Ns	90.1 ± 12.9 (60-140)
ESR (mm/h)	<u>14.6 ± 11.6 (1-87)</u>	<u>0.02</u>	<u>12.3 ± 10.0 (1-61)</u>
CRP** (mg/L)	<u>2.9 ± 3.4 (0-22)</u>	<u>0.001</u>	<u>2.0 ± 2.3 (0-12)</u>
Hematocrit (%)	39.8 ± 4.5 (30-57)	Ns	39.7 ± 4.5 (21-52)

*Irritable bowel syndrome †Nonsignificant ($p > 0.05$) ‡Body mass index §Blood pressures

||Erythrocyte sedimentation rate **C-reactive protein

Discussion

Just after the excess weight, smoking may be the second common cause of vasculitis all over the world. It is a major risk factor for the development of atherosclerotic end-organ insufficiencies including coronary heart disease (CHD), peripheral artery disease (PAD), chronic obstructive pulmonary disease (COPD), chronic renal disease (CRD), cirrhosis, and stroke (13, 15). Its atherosclerotic effect is the most obvious in Buerger's disease. Buerger's disease is an obliterative vasculitis characterized by inflammatory changes in small and medium-sized arteries and veins, and it has never been reported in the absence of smoking in the literature. Although the well-known atherosclerotic effects of smoking, some studies reported that smoking in human being and nicotine administration in animals are associated with lower BMI values (16). Some evidences revealed an increased energy expenditure during smoking both on rest and light physical activity (17), and nicotine supplied by patch after smoking cessation decreased caloric intake in a dose-related manner (18). According to an animal study, nicotine may lengthen intermeal time, and simultaneously decrease amount of meal eaten (19). Additionally, the BMI seems to be the highest in the former, the lowest in the current, and medium in never smokers (20). Smoking may be associated with a postcessation weight gain, but evidences suggest that risk of the weight gain is the highest during the first year after quitting, and decreases with the following years (21). Similarly, although the CHD was detected with similar prevalences in both genders, prevalences of smoking and COPD were higher in males against the higher BMI, low density lipoproteins (LDL), triglycerides, white coat hypertension (WCH), hypertension (HT), and diabetes mellitus (DM) in females (22). This result may indicate both the atherosclerotic and weight decreasing roles of smoking (23). Similarly, the incidence of myocardial infarctions is increased six-fold in women and three-fold in men who smoked at least 20 cigarettes per day (24). In another word, smoking may be more harmful for women about the atherosclerotic end-points probably due to the higher BMI and its consequences in them. Similarly, smoking is consistently higher in men in the literature (15). So smoking is probably a powerful atherosclerotic risk factor with some suppressor effects on appetite. On the other hand, smoking-induced weight loss may be related with the vascular endothelial inflammation all over the body, since loss of appetite is one of the major symptoms of disseminated inflammation in the body. Clinicians can even understand healing of their patients by means of normalizing appetite. Several toxic substances found in cigarette smoke get into the circulation via the respiratory tract, and cause a vascular endothelial inflammation until their clearance from the circulation. But due to the repeated smoking habit of the individuals, the clearance process never terminates. So the patients become ill with loss of appetite, permanently. In another definition, smoking-induced weight loss is an indicator of being ill instead of being healthy (18-20). After smoking cessation, appetite normalizes with a prominent weight gain but the returned weights are their physiological weights, actually. On the other hand, there may be several underlying mechanisms terminating with

the IBS in smokers. First of all, smoking-induced vascular endothelial inflammation may disturb epithelial functions for absorption and excretion in the gastrointestinal and genitourinary tracts. These functional problems may terminate with the symptoms and components of the IBS including loose stool, diarrhea, constipation, and urolithiasis. Secondly, diarrheal losses-induced urinary changes may even cause urolithiasis (6, 7). Thirdly, smoking-induced sympathetic nervous system activation may cause motility disorders in the gastrointestinal and genitourinary tracts. Fourthly, smoking-induced loss of appetite may terminate with obstipation. Finally, immunosuppression secondary to smoking-induced vascular endothelial inflammation may even terminate with gastrointestinal and genitourinary tract infections causing loose stool, diarrhea, and urolithiasis since some types of bacteria can provoke urinary supersaturation and modify the environment to form crystal deposits in the urine. In fact, 10% of urinary stones are struvite stones which are built by magnesium ammonium phosphate produced during infection with bacteria that possess the enzyme, urease. Similarly, urolithiasis was detected in 17.9% of cases with the IBS, whereas this ratio was 11.6% in cases without the IBS ($p < 0.01$) (6).

Chronic endothelial damage may be the major underlying cause of aging and death by causing end-organ insufficiencies in human being (25). Much higher BP of the afferent vasculature may be the major accelerating factor by causing recurrent injuries on vascular endothelium. Probably, whole afferent vasculature including capillaries are mainly involved in the process. Thus the term of venosclerosis is not as famous as atherosclerosis in the literature. Due to the chronic endothelial damage, inflammation, edema, and fibrosis, vascular walls thicken, their lumens narrow, and they lose their elastic natures, those eventually reduce blood supply to the terminal organs, and increase systolic and decrease diastolic BP further. Some of the well-known accelerating factors of the inflammatory process are physical inactivity, sedentary lifestyle, animal-rich diet, excess weight, smoking, alcohol, chronic inflammations, prolonged infections, and cancers for the development of terminal consequences including obesity, HT, DM, cirrhosis, PAD, COPD, CHD, CRD, mesenteric ischemia, osteoporosis, stroke, dementia, other end-organ insufficiencies, early aging, and premature death (26). Although early withdrawal of the accelerating factors can delay terminal consequences, after development of HT, DM, cirrhosis, COPD, CRD, CHD, PAD, mesenteric ischemia, osteoporosis, stroke, dementia, other end-organ insufficiencies, and aging, endothelial changes can not be reversed completely due to their fibrotic natures. The accelerating factors and terminal consequences are researched under the headings of metabolic syndrome, aging syndrome, or accelerated endothelial damage syndrome in the literature, extensively (27, 28).

Obesity may be one of the terminal consequences of the metabolic syndrome since after development of the obesity, nonpharmaceutical approaches provide limited benefit either to heal obesity or to prevent its

complications. Excess weight may cause a chronic low-grade inflammation on vascular endothelium, and risk of death from all causes including cardiovascular diseases and cancers increases parallel to the range of excess weight in all age groups (29). The low-grade chronic inflammatory process may even cause genetic changes on the epithelial cells, and the systemic atherosclerotic process may decrease clearance of malignant cells by the immune system. The effects of excess weight on BP were shown in the literature, extensively (30). For example, incidence of sustained normotension (NT) was higher in the underweight (80.3%) than the normal weight (64.0%, $p < 0.05$) and overweight groups (31.5%, $p < 0.05$), significantly, and 52.8% of cases with HT had obesity against 14.5% of cases with the NT ($p < 0.001$) (31). So the dominant underlying cause of the metabolic syndrome appears as weight gain, which is probably the main cause of insulin resistance, hyperlipoproteinemias, impaired fasting glucose, impaired glucose tolerance, and WCH via the prolonged low-grade inflammation on vascular endothelium all over the body (32). Prevention of the weight gain with physical activity, even in the absence of a prominent weight loss, will probably result with resolution of many parameters of the syndrome (33-36). According to our experiences, excess weight may actually be a consequence of physical inactivity instead of an excessive eating habit, thus prevention of weight gain can not be achieved by diet, alone (37). Additionally, limitation of excess weight as an excessive fat tissue around abdomen under the title of abdominal obesity is meaningless, instead it should be defined as overweight or obesity via the BMI since adipocytes function as an endocrine organ, and they produce a variety of cytokines and hormones all over the body (32). The eventual hyperactivities of sympathetic nervous system and renin-angiotensin-aldosterone system are probably associated with chronic endothelial inflammation, insulin resistance, and elevated BP. Similarly, the Adult Treatment Panel III reported that although some people classified as overweight with larger muscular masses, most of them also have excessive fat tissue predisposing to HT, DM, CHD, and stroke-like terminal end-points of the metabolic syndrome (14).

The acute phase response is a facet of the innate immune system that occurs in response to infections, infarctions, foreign bodies, autoimmune disorders, allergies, neoplasms, traumas, or burns-like stresses of the body. Certain mediators known as APR are increased or decreased during the acute phase response (38, 39). These markers are commonly measured in clinical practice as indicators of acute illnesses. The terms of acute phase proteins and APR are usually used synonymously, although some APR are polypeptides rather than proteins. An acute phase reaction classically presents with fever, tachycardia, and leukocytosis. Positive and negative APR are those whose concentrations increase or decrease during an acute phase response, respectively. The acute phase response is predominantly mediated by the pro-inflammatory cytokines including TNF, IL-1, and IL-6

secreted by the immune cells. In case of inflammations, infections, and tissue damages, neutrophils and macrophages release such cytokines into the circulation. The liver and some other organs respond by producing many positive APR to the cytokines. Some of the well-known positive APR are ESR, CRP, fibrinogen, ferritin, procalcitonin, hepcidin, haptoglobin, ceruloplasmin, complement proteins, and serum amyloid A. CRP is involved in innate immunity, and responsible for activating the complement pathway. Serum CRP rises rapidly, with a maximal concentration reached within two days, and falls quickly once the inflammation has resolved. Measurement of CRP is a useful indicator of inflammations in the clinics. It correlates with ESR, but not always directly. This is due to the ESR being largely dependent on elevation of fibrinogen with a half-life of one week, approximately. Thus ESR remains higher for a longer period of time despite the removal of the inflammatory stimulus. Whereas CRP rises with a half-life of 6-8 hours, rapidly, and then returns to normal in case of a successful treatment, quickly. On the other hand, productions of the negative APR are suppressed at the same time. Some of the well-known negative APR are albumin, transferrin, retinol-binding protein, antithrombin, transcortin, and alpha-fetoprotein. The suppression of such proteins is also used as an indicator of inflammations. Suppression of the synthesis of such proteins may be due to the protection of amino acids for the production of positive APR, sufficiently. Due to the same reason, productions of high density lipoproteins (HDL) and LDL may also be suppressed in the liver during the acute phase responses (40). For example, although the similar mean age, gender distribution, smoking, and BMI in both groups, triglycerides, DM, and CHD were higher whereas LDL were lower in patients with plasma HDL values of lower than 40 mg/dL, significantly (40). So HDL and LDL may actually behave as negative APR in the plasma. Similarly, although the lower mean age, BMI, fasting plasma glucose, and LDL, the highest CHD of the group with HDL values of lower than 40 mg/dL can also be explained by the same hypothesis (41). Beside that although the mean triglycerides, fibrinogen, CRP, and glucose values were higher in cases with ischemic stroke, the oxidized LDL values did not correlate with the mean age, stroke severity, and outcome in another study (42). Additionally, significant alterations occurred in the lipid metabolism and compositions of the lipoproteins, and plasma triglycerides increased whereas HDL and LDL decreased during infections (43). Furthermore, a 10 mg/dL increase of plasma LDL values was associated with a 3% lower risk of hemorrhagic stroke in another study (44). Similarly, the highest prevalences of HT and DM parallel to the increased values of LDL and HDL, and the highest prevalences of COPD, CHD, and CRD in contrast to the lowest values of LDL and HDL may show initially positive but eventually negative APR natures of LDL and HDL in the plasma (45). So the most desired values were between 80 and 100 mg/dL for LDL, between 40 and 46 mg/dL for HDL, and lower than 60 mg/dL for triglycerides in the plasma (41).

As a conclusion, probably IBS is a low-grade inflammatory process initiated by smoking, infections, inflammations, anxiety, depression, sleep disorders, illness fear, and cancer fear-like stresses, and eventually terminates with dysfunctions of the gastrointestinal and genitourinary tracts and elevations of ESR and CRP-like APR in the plasma. The elevated APR will probably terminate with an accelerated atherosclerotic process all over the body and a shortened survival in both genders.

References

1. Valenkevich LN, Iakhontov OI. Modern myths of clinical gastroenterology. *Eksp Klin Gastroenterol* 2004; 105(3): 72-4.
2. Rhee PL. Definition and epidemiology of irritable bowel syndrome. *Korean J Gastroenterol* 2006; 47(2): 94-100.
3. Lee OY. Psychosocial factors and visceral hypersensitivity in irritable bowel syndrome. *Korean J Gastroenterol* 2006; 47(2): 111-9.
4. Wang W, Pan G, Qian J. Effect of psychological factors on visceral sensation of patients with irritable bowel syndrome. *Zhonghua Yi Xue Za Zhi* 2002(5); 82: 308-11.
5. Park H. The pathophysiology of irritable bowel syndrome: inflammation and motor disorder. *Korean J Gastroenterol* 2006; 47(2): 101-10.
6. Helvaci MR, Kabay S, Gulcan E. A physiologic events' cascade, irritable bowel syndrome, may even terminate with urolithiasis. *J Health Sci* 2006; 52(4): 478-81.
7. Helvaci MR, Algin MC, Kaya H. Irritable bowel syndrome and chronic gastritis, hemorrhoid, urolithiasis. *Eurasian J Med* 2009; 41(3): 158-61.
8. Helvaci MR, Kaya H, Algin MC, Yalcin A. A physiologic events' cascade: irritable bowel syndrome may even terminate with chronic gastritis. *Med J Malaysia* 2008; 63(2): 140-2.
9. Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, et al. Activation of the mucosal immune system in irritable bowel syndrome. *Gastroenterology* 2002; 122(7): 1778-83.
10. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. *Gastroenterology* 2004; 126(3): 693-702.
11. Tornblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. *Gastroenterology* 2002; 123(6): 1972-9.
12. Wahnschaffe U, Ullrich R, Riecken EO, Schulzke JD. Celiac disease-like abnormalities in a subgroup of patients with irritable bowel syndrome. *Gastroenterology* 2001; 121(6): 1329-38.
13. Helvaci MR, Aydin Y, Gundogdu M. Smoking induced atherosclerosis in cancers. *HealthMED* 2012; 6(11): 3744-9.
14. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 2002; 106(25): 3143-421.
15. Fodor JG, Tzerovska R, Dorner T, Rieder A. Do we diagnose and treat coronary heart disease differently in men and women? *Wien Med Wochenschr* 2004; 154(17-18): 423-5.
16. Grunberg NE, Greenwood MR, Collins F, Epstein LH, Hatsukami D, Niaura R, et al. National working conference on smoking and body weight. Task Force 1: Mechanisms relevant to the relations between cigarette smoking and body weight. *Health Psychol* 1992; 11: 4-9.
17. Walker JF, Collins LC, Rowell PP, Goldsmith LJ, Moffatt RJ, Stamford BA. The effect of smoking on energy expenditure and plasma catecholamine and nicotine levels during light physical activity. *Nicotine Tob Res* 1999; 1(4): 365-70.
18. Hughes JR, Hatsukami DK. Effects of three doses of transdermal nicotine on post-cessation eating, hunger and weight. *J Subst Abuse* 1997; 9: 151-9.
19. Miyata G, Meguid MM, Varma M, Fetissov SO, Kim HJ. Nicotine alters the usual reciprocity between meal size and meal number in female rat. *Physiol Behav* 2001; 74(1-2): 169-76.
20. Laaksonen M, Rahkonen O, Prattala R. Smoking status and relative weight by educational level in Finland, 1978-1995. *Prev Med* 1998; 27(3): 431-7.
21. Fromm P, Melamed S, Benbassat J. Smoking cessation and weight gain. *J Fam Pract* 1998; 46(6): 460-4.
22. Helvaci MR, Kaya H, Gundogdu M. Gender differences in coronary heart disease in Turkey. *Pak J Med Sci* 2012; 28(1): 40-4.
23. Helvaci MR, Aydin Y, Gundogdu M. Atherosclerotic effects of smoking and excess weight. *J Obes Wt Loss Ther* 2012; 2:145.
24. Prescott E, Hippe M, Schnohr P, Hein HO, Vestbo J. Smoking and risk of myocardial infarction in women and men: longitudinal population study. *BMJ* 1998; 316(7137): 1043-7.
25. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. *Lancet* 2005; 365(9468): 1415-28.
26. Widlansky ME, Gokce N, Keaney JF Jr, Vita JA. The clinical implications of endothelial dysfunction. *J Am Coll Cardiol* 2003; 42(7): 1149-60.
27. Helvaci MR, Aydin LY, Aydin Y. Digital clubbing may be an indicator of systemic atherosclerosis even at microvascular level. *HealthMED* 2012; 6(12): 3977-81.
28. Anderson RN, Smith BL. Deaths: leading causes for 2001. *Natl Vital Stat Rep* 2003; 52(9): 1-85.

29. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. *N Engl J Med* 1999; 341(15): 1097-105.
30. Helvaci MR, Kaya H, Yalcin A, Kuvandik G. Prevalence of white coat hypertension in underweight and overweight subjects. *Int Heart J* 2007; 48(5): 605-13.
31. Helvaci MR, Kaya H, Duru M, Yalcin A. What is the relationship between white coat hypertension and dyslipidemia? *Int Heart J* 2008; 49(1): 87-93.
32. Franklin SS, Barboza MG, Pio JR, Wong ND. Blood pressure categories, hypertensive subtypes, and the metabolic syndrome. *J Hypertens* 2006; 24(10): 2009-16.
33. Azadbakht L, Mirmiran P, Esmailzadeh A, Azizi T, Azizi F. Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. *Diabetes Care* 2005; 28(12): 2823-31.
34. Helvaci MR, Ayyildiz O, Gundogdu M, Aydin Y, Abyad A, Pocock L. Excess weight or smoking. *World Family Med* 2018; 16(10): 14-9.
35. Helvaci MR, Ayyildiz O, Gundogdu M, Aydin Y, Abyad A, Pocock L. Body mass and blood pressure. *World Family Med* 2019; 17(1): 36-40.
36. Helvaci MR, Kaya H, Borazan A, Ozer C, Seyhanli M, Yalcin A. Metformin and parameters of physical health. *Intern Med* 2008; 47(8): 697-703.
37. Helvaci MR, Algin MC, Abyad A, Pocock L. Physical inactivity or an excessive eating habit. *Middle East J Nursing* 2018; 12(1): 14-8.
38. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. *N Engl J Med* 1999; 340(6): 448-54.
39. Wool GD, Reardon CA. The influence of acute phase proteins on murine atherosclerosis. *Curr Drug Targets* 2007; 8(11): 1203-14.
40. Helvaci MR, Abyad A, Pocock L. High and low density lipoproteins may be negative acute phase proteins of the metabolic syndrome. *Middle East J Nursing* 2020; 14(1): 10-6.
41. Helvaci MR, Yapyak M, Tasci N, Abyad A, Pocock L. The most desired values of high and low density lipoproteins and triglycerides in the plasma. *World Family Med* 2020; 18(8): 21-7.
42. Vibo R, Körv J, Roose M, Kampus P, Muda P, Zilmer K, et al. Acute phase proteins and oxidised low-density lipoprotein in association with ischemic stroke subtype, severity and outcome. *Free Radic Res* 2007; 41(3): 282-7.
43. Pirillo A, Catapano AL, Norata GD. HDL in infectious diseases and sepsis. *Handb Exp Pharmacol* 2015; 224: 483-508.
44. Ma C, Na M, Neumann S, Gao X. Low-density lipoprotein cholesterol and risk of hemorrhagic stroke: a systematic review and dose-response meta-analysis of prospective studies. *Curr Atheroscler Rep* 2019; 21(12): 52.
45. Helvaci MR, Abyad A, Pocock L. The safest values of low density lipoproteins in the plasma. *World Family Med* 2020; 18(4): 18-24.